Zydus Wellness Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 15, 2025, 7:26 pm

Quick Insight

Zydus Wellness Ltd, with a market capitalization of 12,414 Cr. and a share price of 1,949, presents a mixed financial picture. The company's P/E ratio of 38.6 indicates a relatively high valuation, while the ROE and ROCE stand at 6.02% and 6.16%, respectively, reflecting moderate returns. With an OPM of 18% and a net profit of 347 Cr., Zydus shows operational efficiency despite a lower ROE and ROCE. The company's strong promoter holding of 69.62% provides stability, although FII and DII holdings are relatively low. With healthy reserves of 5,608 Cr. and a manageable level of borrowings at ₹188 Cr., Zydus appears well-positioned to navigate challenges. The P/BV ratio of 1.75x and ICR of 13.42x suggest a reasonable valuation and good debt coverage. Overall, Zydus Wellness Ltd seems to have a stable financial footing, but investors should keep an eye on improving operational efficiency to enhance returns and long-term value.

Competitors of Zydus Wellness Ltd

All Competitor Stocks of Zydus Wellness Ltd

Quarterly Result

Last Updated: August 2, 2025, 1:05 am

Below is a detailed analysis of the quarterly data for Zydus Wellness Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 861.00 Cr.. The value appears to be declining and may need further review. It has decreased from 913.00 Cr. (Mar 2025) to 861.00 Cr., marking a decrease of 52.00 Cr..
• For Expenses, as of Jun 2025, the value is 705.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 723.00 Cr. (Mar 2025) to 705.00 Cr., marking a decrease of 18.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 156.00 Cr.. The value appears to be declining and may need further review. It has decreased from 190.00 Cr. (Mar 2025) to 156.00 Cr., marking a decrease of 34.00 Cr..
• For OPM %, as of Jun 2025, the value is 18.00%. The value appears to be declining and may need further review. It has decreased from 21.00% (Mar 2025) to 18.00%, marking a decrease of 3.00%.
• For Other Income, as of Jun 2025, the value is 3.00 Cr.. The value appears strong and on an upward trend. It has increased from 1.00 Cr. (Mar 2025) to 3.00 Cr., marking an increase of 2.00 Cr..
• For Interest, as of Jun 2025, the value is 2.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 4.00 Cr. (Mar 2025) to 2.00 Cr., marking a decrease of 2.00 Cr..
• For Depreciation, as of Jun 2025, the value is 11.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 13.00 Cr. (Mar 2025) to 11.00 Cr., marking a decrease of 2.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 145.00 Cr.. The value appears to be declining and may need further review. It has decreased from 173.00 Cr. (Mar 2025) to 145.00 Cr., marking a decrease of 28.00 Cr..
• For Tax %, as of Jun 2025, the value is 12.00%. The value appears to be increasing, which may not be favorable. It has increased from 1.00% (Mar 2025) to 12.00%, marking an increase of 11.00%.
• For Net Profit, as of Jun 2025, the value is 128.00 Cr.. The value appears to be declining and may need further review. It has decreased from 172.00 Cr. (Mar 2025) to 128.00 Cr., marking a decrease of 44.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 20.10. The value appears to be declining and may need further review. It has decreased from 27.01 (Mar 2025) to 20.10, marking a decrease of 6.91.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: July 22, 2025, 4:16 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: June 16, 2025, 12:35 pm

Below is a detailed analysis of the balance sheet data for Zydus Wellness Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 64.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 64.00 Cr..
• For Reserves, as of Mar 2025, the value is 5,608.00 Cr.. The value appears strong and on an upward trend. It has increased from 5,294.00 Cr. (Mar 2024) to 5,608.00 Cr., marking an increase of 314.00 Cr..
• For Borrowings, as of Mar 2025, the value is 188.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 329.00 Cr. (Mar 2024) to 188.00 Cr., marking a decrease of 141.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 582.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 462.00 Cr. (Mar 2024) to 582.00 Cr., marking an increase of 120.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 6,442.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6,148.00 Cr. (Mar 2024) to 6,442.00 Cr., marking an increase of 294.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 5,125.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,708.00 Cr. (Mar 2024) to 5,125.00 Cr., marking an increase of 417.00 Cr..
• For CWIP, as of Mar 2025, the value is 15.00 Cr.. The value appears strong and on an upward trend. It has increased from 10.00 Cr. (Mar 2024) to 15.00 Cr., marking an increase of 5.00 Cr..
• For Investments, as of Mar 2025, the value is 36.00 Cr.. The value appears to be declining and may need further review. It has decreased from 78.00 Cr. (Mar 2024) to 36.00 Cr., marking a decrease of 42.00 Cr..
• For Other Assets, as of Mar 2025, the value is 1,266.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,354.00 Cr. (Mar 2024) to 1,266.00 Cr., marking a decrease of 88.00 Cr..
• For Total Assets, as of Mar 2025, the value is 6,442.00 Cr.. The value appears strong and on an upward trend. It has increased from 6,148.00 Cr. (Mar 2024) to 6,442.00 Cr., marking an increase of 294.00 Cr..

Notably, the Reserves (5,608.00 Cr.) exceed the Borrowings (188.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Zydus Wellness Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 24, the value is 41.94. This value is within the healthy range. It has decreased from 48.78 (Mar 23) to 41.94, marking a decrease of 6.84.
• For Diluted EPS (Rs.), as of Mar 24, the value is 41.94. This value is within the healthy range. It has decreased from 48.78 (Mar 23) to 41.94, marking a decrease of 6.84.
• For Cash EPS (Rs.), as of Mar 24, the value is 45.71. This value is within the healthy range. It has decreased from 52.71 (Mar 23) to 45.71, marking a decrease of 7.00.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 842.37. It has increased from 805.07 (Mar 23) to 842.37, marking an increase of 37.30.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 842.37. It has increased from 805.07 (Mar 23) to 842.37, marking an increase of 37.30.
• For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 366.01. It has increased from 354.36 (Mar 23) to 366.01, marking an increase of 11.65.
• For PBDIT / Share (Rs.), as of Mar 24, the value is 50.64. This value is within the healthy range. It has decreased from 53.75 (Mar 23) to 50.64, marking a decrease of 3.11.
• For PBIT / Share (Rs.), as of Mar 24, the value is 46.90. This value is within the healthy range. It has decreased from 49.82 (Mar 23) to 46.90, marking a decrease of 2.92.
• For PBT / Share (Rs.), as of Mar 24, the value is 40.90. This value is within the healthy range. It has decreased from 45.71 (Mar 23) to 40.90, marking a decrease of 4.81.
• For Net Profit / Share (Rs.), as of Mar 24, the value is 41.97. This value is within the healthy range. It has decreased from 48.78 (Mar 23) to 41.97, marking a decrease of 6.81.
• For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 41.97. This value is within the healthy range. It has decreased from 48.78 (Mar 23) to 41.97, marking a decrease of 6.81.
• For PBDIT Margin (%), as of Mar 24, the value is 13.83. This value is within the healthy range. It has decreased from 15.16 (Mar 23) to 13.83, marking a decrease of 1.33.
• For PBIT Margin (%), as of Mar 24, the value is 12.81. This value is within the healthy range. It has decreased from 14.05 (Mar 23) to 12.81, marking a decrease of 1.24.
• For PBT Margin (%), as of Mar 24, the value is 11.17. This value is within the healthy range. It has decreased from 12.89 (Mar 23) to 11.17, marking a decrease of 1.72.
• For Net Profit Margin (%), as of Mar 24, the value is 11.46. This value exceeds the healthy maximum of 10. It has decreased from 13.76 (Mar 23) to 11.46, marking a decrease of 2.30.
• For NP After MI And SOA Margin (%), as of Mar 24, the value is 11.46. This value is within the healthy range. It has decreased from 13.76 (Mar 23) to 11.46, marking a decrease of 2.30.
• For Return on Networth / Equity (%), as of Mar 24, the value is 4.98. This value is below the healthy minimum of 15. It has decreased from 6.05 (Mar 23) to 4.98, marking a decrease of 1.07.
• For Return on Capital Employeed (%), as of Mar 24, the value is 5.54. This value is below the healthy minimum of 10. It has decreased from 6.16 (Mar 23) to 5.54, marking a decrease of 0.62.
• For Return On Assets (%), as of Mar 24, the value is 4.34. This value is below the healthy minimum of 5. It has decreased from 5.32 (Mar 23) to 4.34, marking a decrease of 0.98.
• For Long Term Debt / Equity (X), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 23) which recorded 0.00.
• For Total Debt / Equity (X), as of Mar 24, the value is 0.06. This value is within the healthy range. It has increased from 0.05 (Mar 23) to 0.06, marking an increase of 0.01.
• For Asset Turnover Ratio (%), as of Mar 24, the value is 0.38. It has increased from 0.05 (Mar 23) to 0.38, marking an increase of 0.33.
• For Current Ratio (X), as of Mar 24, the value is 1.62. This value is within the healthy range. It has increased from 1.31 (Mar 23) to 1.62, marking an increase of 0.31.
• For Quick Ratio (X), as of Mar 24, the value is 1.02. This value is within the healthy range. It has increased from 0.65 (Mar 23) to 1.02, marking an increase of 0.37.
• For Inventory Turnover Ratio (X), as of Mar 24, the value is 2.24. This value is below the healthy minimum of 4. It has increased from 0.89 (Mar 23) to 2.24, marking an increase of 1.35.
• For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 11.91. This value is below the healthy minimum of 20. It has increased from 10.25 (Mar 23) to 11.91, marking an increase of 1.66.
• For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 10.93. This value is below the healthy minimum of 20. It has increased from 9.48 (Mar 23) to 10.93, marking an increase of 1.45.
• For Earning Retention Ratio (%), as of Mar 24, the value is 88.09. This value exceeds the healthy maximum of 70. It has decreased from 89.75 (Mar 23) to 88.09, marking a decrease of 1.66.
• For Cash Earning Retention Ratio (%), as of Mar 24, the value is 89.07. This value exceeds the healthy maximum of 70. It has decreased from 90.52 (Mar 23) to 89.07, marking a decrease of 1.45.
• For Interest Coverage Ratio (X), as of Mar 24, the value is 13.42. This value is within the healthy range. It has decreased from 21.27 (Mar 23) to 13.42, marking a decrease of 7.85.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 12.71. This value is within the healthy range. It has decreased from 20.93 (Mar 23) to 12.71, marking a decrease of 8.22.
• For Enterprise Value (Cr.), as of Mar 24, the value is 9,439.42. It has decreased from 10,116.33 (Mar 23) to 9,439.42, marking a decrease of 676.91.
• For EV / Net Operating Revenue (X), as of Mar 24, the value is 4.05. This value exceeds the healthy maximum of 3. It has decreased from 4.49 (Mar 23) to 4.05, marking a decrease of 0.44.
• For EV / EBITDA (X), as of Mar 24, the value is 29.31. This value exceeds the healthy maximum of 15. It has decreased from 29.58 (Mar 23) to 29.31, marking a decrease of 0.27.
• For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 4.02. This value exceeds the healthy maximum of 3. It has decreased from 4.37 (Mar 23) to 4.02, marking a decrease of 0.35.
• For Retention Ratios (%), as of Mar 24, the value is 88.08. This value exceeds the healthy maximum of 70. It has decreased from 89.74 (Mar 23) to 88.08, marking a decrease of 1.66.
• For Price / BV (X), as of Mar 24, the value is 1.75. This value is within the healthy range. It has decreased from 1.93 (Mar 23) to 1.75, marking a decrease of 0.18.
• For Price / Net Operating Revenue (X), as of Mar 24, the value is 4.02. This value exceeds the healthy maximum of 3. It has decreased from 4.37 (Mar 23) to 4.02, marking a decrease of 0.35.
• For EarningsYield, as of Mar 24, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 23) to 0.02, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness